

CRTC2 Antibody (N-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP14321a

Product Information

Application Primary Accession	WB, IHC-P, E <u>Q53ET0</u>
Other Accession	<u>NP_859066.1</u>
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Clone Names	RB20150
Calculated MW	73302
Antigen Region	94-123

Additional Information

Gene ID	200186
Other Names	CREB-regulated transcription coactivator 2, Transducer of regulated cAMP response element-binding protein 2, TORC-2, Transducer of CREB protein 2, CRTC2, TORC2
Target/Specificity	This CRTC2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 94-123 amino acids from the N-terminal region of human CRTC2.
Dilution	WB~~1:1000 IHC-P~~1:100~500 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	CRTC2 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	CRTC2
Synonyms	TORC2

Function	Transcriptional coactivator for CREB1 which activates transcription through both consensus and variant cAMP response element (CRE) sites. Acts as a coactivator, in the SIK/TORC signaling pathway, being active when dephosphorylated and acts independently of CREB1 'Ser-133' phosphorylation. Enhances the interaction of CREB1 with TAF4. Regulates gluconeogenesis as a component of the LKB1/AMPK/TORC2 signaling pathway. Regulates the expression of specific genes such as the steroidogenic gene, StAR. Potent coactivator of PPARGC1A and inducer of mitochondrial biogenesis in muscle cells. Also coactivator for TAX activation of the human T-cell leukemia virus type 1 (HTLV-1) long terminal repeats (LTR).
Cellular Location	Cytoplasm. Nucleus. Note=Translocated from the nucleus to the cytoplasm on interaction of the phosphorylated form with 14-3-3 protein (PubMed:15454081). In response to cAMP levels and glucagon, relocated to the nucleus (PubMed:15454081)
Tissue Location	Most abundantly expressed in the thymus. Present in both B and T-lymphocytes. Highly expressed in HEK293T cells and in insulinomas. High levels also in spleen, ovary, muscle and lung, with highest levels in muscle. Lower levels found in brain, colon, heart, kidney, prostate, small intestine and stomach. Weak expression in liver and pancreas.


Background


Transcriptional coactivator for CREB1 which activates transcription through both consensus and variant cAMP response element (CRE) sites. Acts as a coactivator, in the SIK/TORC signaling pathway, being active when dephosphorylated and acts independently of CREB1 'Ser-133' phosphorylation. Enhances the interaction of CREB1 with TAF4. Regulates gluconeogenesis as a component of the LKB1/AMPK/TORC2 signaling pathway. Regulates the expression of specific genes such as the steroidogenic gene, StAR. Potent coactivator of PPARGC1A and inducer of mitochondrial biogenesis in muscle cells. Also coactivator for TAX activation of the human T-cell leukemia virus type 1 (HTLV-1) long terminal repeats (LTR).

References

Nakatsu, Y., et al. J. Biol. Chem. 285(43):33018-33027(2010) Kaizuka, T., et al. J. Biol. Chem. 285(26):20109-20116(2010) Lyo, D., et al. Biochem. Biophys. Res. Commun. 396(2):562-565(2010) Lu, M., et al. J. Am. Soc. Nephrol. 21(5):811-818(2010) Roulin, D., et al. Mol. Cancer 9, 57 (2010) :

Images





#AP14321a)immunohistochemistry analysis in formalin fixed and paraffin embedded human placenta tissue followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of CRTC2 Antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.